In a bilateral MC38 tumor model, treatment with MnOx@HMSN (CDA+Adpgk) outperformed a soluble mixture of CDA, Adpgk, and Mn2+, demonstrating potent local and abscopal antitumor effects.[100f] These findings highlight MnOx@HMSN as a robust nanoplatform for enhancing the efficacy of CDN‐based cancer vaccines, offering a robust strategy to amplify immune responses and improve therapeutic outcomes. The gene discussed is ADPGK; the disease is cancer.